CHO Plus Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 9

Employees

  • Latest Deal Type
  • 2ndary - Private

  • Financing Rounds
  • 8

CHO Plus General Information

Description

Developer of genetically engineered mammalian cells designed for the production of therapeutic proteins and viruses. The company utilizes patented technologies for cell engineering, genome transcription hotspots, and efficient clone screening, enabling biopharmaceutical companies to achieve higher productivity, reduce production costs, and enhance the capacity of existing manufacturing processes.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Private Equity-Backed
Corporate Office
  • 329 Oyster Point Boulevard
  • South San Francisco, CA 94080
  • United States
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • 329 Oyster Point Boulevard
  • South San Francisco, CA 94080
  • United States

CHO Plus Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

CHO Plus Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore CHO Plus‘s full profile, request access.

Request a free trial

CHO Plus Patents

CHO Plus Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2025265147-A1 Packaging cells with tunable and leakproof gene expression to optimize production of aav vectors Pending 21-Jun-2024
US-20260071231-A1 Viral vector packaging cells with tunable virus genes to optimize vector production and quality Pending 21-Jun-2024
EP-4824240-A1 High production of recombinant protein by making cell hybrids and enriching for a preferred mitochondrial phenotype Pending 13-Dec-2023
WO-2025128096-A1 High production of recombinant protein by making cell hybrids and enriching for a preferred mitochondrial phenotype Inactive 13-Dec-2023
AU-2023284396-A1 Cell hybrids as host cells for high efficiency production of gene therapy vectors and viral vaccines Pending 09-Jun-2022 C12N5/0686
To view CHO Plus’s complete patent history, request access »

CHO Plus Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

CHO Plus Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore CHO Plus‘s full profile, request access.

Request a free trial

CHO Plus FAQs

  • When was CHO Plus founded?

    CHO Plus was founded in 2014.

  • Where is CHO Plus headquartered?

    CHO Plus is headquartered in South San Francisco, CA.

  • What is the size of CHO Plus?

    CHO Plus has 9 total employees.

  • What industry is CHO Plus in?

    CHO Plus’s primary industry is Biotechnology.

  • Is CHO Plus a private or public company?

    CHO Plus is a Private company.

  • What is CHO Plus’s current revenue?

    The current revenue for CHO Plus is .

  • How much funding has CHO Plus raised over time?

    CHO Plus has raised $440K.

  • Who are CHO Plus’s investors?

    MedTech Innovator, BioTools Innovator, Johnson & Johnson Innovation - JLABS, MBC BioLabs, and LEONID are 5 of 6 investors who have invested in CHO Plus.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process